key: cord-0963750-37740tm0 authors: Maison, David P; Nerurkar, Vivek R title: Research Methodology to Define the Introduction of the SARS-CoV-2 B.1.429 Variant in Hawaii date: 2021-04-01 journal: Res Sq DOI: 10.21203/rs.3.rs-378702/v1 sha: bf1332af30e062ce40a146cebb5e65e927383a20 doc_id: 963750 cord_uid: 37740tm0 Here, we present a methodology to define the origin of SARS-CoV-2 variants as exemplified by defining the introduction of the B.1.429 variant in Hawaii. We used 187 B.1.429 variant sequences from Hawai’i deposited in the GenBank and GISAID as of March 20, 2021, as an example to develop the methodology. Briefly, i) acquire sequences, ii) perform multiple sequence alignment, iii) trim the alignment, iv) remove incomplete sequences, v) remove duplicates, and vi) generate a phylogenetic tree. The tree defined the most recent common ancestor as the origin. Further, the multiple sequence alignment used to generate the phylogenetic tree identified 20 single nucleotide polymorphisms in the B.1.429 variant genome. The Centers for Disease Control and Prevention defines B.1.429 as a variant initially found in California. This variant was introduced in Hawai’i multiple times in early 2021. Based on the phylogenetic tree, we conclude that the B.1.429 variant has entered Hawai’i at different timepoints from at least seven different states in the continental United States. This information provides a tool for policy makers and public health officials in applying precision public health genomics. states in the continental United States. This information provides a tool for policy makers and public health o cials in applying precision public health genomics. Precision public health genomics is a public health policy tool to track the spread of viruses. 1 In this age of information, precision public health genomics has been used as a public policy tool during the West Africa Ebola Outbreak from 2014-2016. 1 During the current Coronavirus Disease 2019 pandemic, for precision public health genomics to be effective, it requires high-speed and low-cost data analysis. Since January 2020, over 1 million SARS-CoV-2 whole-genome sequences have been deposited in the GenBank and global initiative on sharing all in uenza data (GISAID). A fast, effective, consistent, and economical method is required to analyze the vast amount of SARS-CoV-2 sequences and to determine the origin of SARS-CoV-2 variants and lineages in populations. Several researchers do not have access to the supercomputing infrastructure necessary to conduct the phylogenetic analysis to determine the introduction of SARS-CoV-2 in a population and assign its origin. A simpli ed method is required to de ne the origin of SARS-CoV-2 lineages and variants using a personal computer. Using B.1.429 variant as an example, initially found in California and later identi ed in Hawai'i, 2 we demonstrate a method to de ne the origin of SARS-CoV-2 lineages and variants using a personal computer. This method uses a combination of free online services and purchasable software. The nomenclature system developed by Rambaut and colleagues 3 for SARS-CoV-2 lineages to assist genomic epidemiology has allowed for manageable and e cient partitioning of sequences for rapid determination of SARS-CoV-2 origin. This method partitions sequences by Pangolin Lineages into manageable multiple sequence alignments (MSA) to perform phylogenetic analysis. 3 Methods: Here, we present a method to de ne SARS-CoV-2 variants' origin. We used 187 B.1.429 variant sequences from Hawai'i deposited as of March 20, 2021, in the GenBank and GISAID as an example. In brief, the method includes: 1) The lineage-de ning sequences of SARS-CoV-2 Lineage A and Lineage B are used as ancestral roots. 3 Lineage A (EPI_ISL_406801) is acquired from GISAID and Lineage B (MN908947) is acquired from GenBank. 2) To identify lineages of interest in an area, lter GISAID by location (e.g.: North America/USA/Hawaii) and download all sequences. GISAID sequences were downloaded in batches due to GISAID maximum download size. Similarly, all geographically similar sequences reported in GenBank were downloaded using the search term SARS-CoV-2 and state abbreviation (e.g.: "SARS-CoV-2 HI") and the lter sequence length (20,000-40,000). 3) Combine the GISAID and GenBank sequences into one .fasta le and assign lineages using Pangolin Lineage Assigner (pangolin.cog-uk.io). 3 Remove the newly added MN908947 sequence that MAFFT places at the beginning of the alignment, if not MN908947 sequence will be removed by the sRNAtoolbox in a later step and Lineage B will not be represented as an ancestral root in the phylogenetic tree. 9) Import MSA le into Geneious Prime 2021.0.3 ( http://www . geneious.com), search for the orf1a 5' start of the entire alignment (5'atggagagccttgtccctggtttca-3') and remove the 5' untranslated region (UTR) by deleting the upstream region (~ 265 bp) from the MSA. Next, search for ORF10 3' end (5'-tgtagttaactttaatctcacatag-3') and remove the entire 3' UTR by deleting the downstream region (~ 229 bp) from the MSA. 10) Create a duplicate le for the MN908947 sequence and remove the 5' UTR and 3' UTR from MN908947 based upon the aforementioned MSA. 11) Using MAFFT, load the trimmed MSA with the trimmed MN908947 as a reference and remove uninformative single sequences, e.g. uncalled nucleotides 'n.' Set the parameter in the MAFFT at > 0%. 12) Again, remove the additional MN908947 sequence that MAFFT places at the beginning of the alignment. 13) Using sRNAtoolbox ( https://arn.ugr.es/srnatoolbox/helper/removedup/) , 9 load the updated alignment to remove duplicate sequences and merge identi cations (ID) (accession) of duplicates. This merger will create "appendages" in the phylogenetic tree where identical sequences will be lined up together with equal signs (=). 14) Import the nal alignment into Geneious Prime and create approximately maximum-likelihood phylogenetic tree using FastTree program. 10 Additionally, assign Lineage B as the reference sequence, and use the Geneious Prime "Find Variations/SNPs" Annotate and Predict function to identify consensus SNPs. Input SNPs into the SnapGene (Insightful Science, snapgene.com) to identify the nucleotide and amino acid number and substitution as described previously. 11 Results: Within the S gene of the B.1.429 variant, there is a consensus of four non-synonymous amino acid substitutions (S13I, W152C, L452R, D614G). The effects of S13I and W152C substitutions have yet to be determined. Neither of these mutations were found in more than 5% of all published GISAID sequences as of February 2021. The L452R substitution originating in North America did so in Los Angeles (EPI_ISL_1303471), and is considered a substitution of two variants of concern (B. 1.427 and B.1.429) . 12 The CDC notes that these variants correlate to ~ 20% increased transmissibility of SARS-CoV-2, 13 and has reduced neutralization using convalescent sera, vaccinated sera, and sera from patients treated with therapeutics. 12 The D614G substitution, near ubiquitous among all SARS-CoV-2 sequences, is noted for increasing the tness of SARS-CoV-2. 14 This method demonstrates the critical importance of high quality sequencing and the need for enrichment and deep coverage, as over 76% of B.1.429 published sequences worldwide are uninformative phylogenetically due to incompleteness. For example, the rst B.1.429 sequence deposited from Hawaii was from a sample collected on December 31, 2020 (EPI_ISL_967766). Without resequencing the whole genome, or targeting this ambiguous region with Sanger sequencing, this sequence is currently unable to be used in phylogenetics due to ambiguous nucleotides in the S gene. While uninformative sequences may be useful for tracking speci c mutations, they are not useful in tracking variants. Moreover, our methodology demonstrates the ability of sequencing and phylogenetic analysis to provide precision public health genomics in policy-making decisions. That is, as SARS-CoV-2 variants spread asymptomatically across the United States, it is important to use methods for fast and accurate SARS-CoV-2 variant, lineage, and origin assignment. FastTree is not the most stringent method for phylogenetic analysis as the bootstrapping method is not applied, 15 even though it is one of the fastest in generating an approximately maximum-likelihood tree. 16 FastTree is suited for large-scale phylogeny estimation, a critical component of this pandemic. 16 Other phylogenetic softwares require substantial computational infrastructure and time to perform bootstrap analysis. Given the real-time introduction and spread of variants, a program capable of generating trees in a short amount of time without personal access to a supercomputer is warranted. Additionally, FastTree allows appendages to exist, linking identical sequences' accession identi ers -a necessary step for the number of available SARS-CoV-2 sequences and the sequence in ux. Con icts of Interest: The authors report no con icts of interest. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands New COVID variant found in Hawaii, while uptick on Maui attributed to predominate California variant A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology pangolin: lineage assignment in an emerging pandemic as an epidemiological tool. PANGO lineages Centre for Genomic Pathogen Surveillance pangolin.cog-uk MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization MAFFT-DASH: integrated protein sequence and structural alignment MAFFT version 7 -Multiple alignment program for amino acid or nucleotide sequences sRNAbench and sRNAtoolbox 2019: intuitive fast small RNA pro ling and differential expression FastTree: Computing Large Minimum Evolution Trees with Pro les instead of a Distance Matrix Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawaii Reveals the Worldwide Emerging P681H Mutation Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv